Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$18.00 USD
+0.27 (1.52%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.17 +0.17 (0.94%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.00 USD
+0.27 (1.52%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.17 +0.17 (0.94%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Zacks News
Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -85.34% and -27.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
by Zacks Equity Research
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
Earnings Preview: Arcturus Therapeutics (ARCT) Q4 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
by Zacks Equity Research
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
Beat Your Portfolio Fatigue by Dumping These Toxic Stocks
by Rimmi Singhi
Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.
Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
7 Nasdaq ETFs to Play the Index's Winning Momentum
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Nasdaq Hits 13,000 for the First Time: ETFs to Bet On
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
by Zacks Equity Research
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?